Approval of Alzheimer’s drug “rife with irregularities”
US drug regulators failed to follow their own guidance and practices when they approved the controversial Alzheimer’s drug Aduhelm, a congressional report said on Thursday. www.theguardian.com/us-news/2022/dec/29/biogen-fda-alzheimers-aduhelm-congressional-report? The US food and drug administration’s (FDA) process of approval, it said, had been “rife with irregularities”, and the FDA’s interactions with maker Biogen had been “atypical”. The report …
Approval of Alzheimer’s drug “rife with irregularities” Read More »
